BLT2 Is Upregulated in Allergen-Stimulated Mast Cells and Mediates the Synthesis of Th2 Cytokines

Kyung-Jin Cho, Ji-Min Seo, Min-Goo Lee and Jae-Hong Kim

*J Immunol* 2010; 185:6329-6337; Prepublished online 15 October 2010;
doi: 10.4049/jimmunol.1001213
http://www.jimmunol.org/content/185/10/6329

Supplementary Material
http://www.jimmunol.org/content/suppl/2010/10/15/jimmunol.1001213.DC1

References
This article cites 45 articles, 16 of which you can access for free at:
http://www.jimmunol.org/content/185/10/6329.full#ref-list-1

Why *The JI*? Submit online.

- **Rapid Reviews! 30 days** from submission to initial decision
- **No Triage!** Every submission reviewed by practicing scientists
- **Fast Publication!** 4 weeks from acceptance to publication

*average

Subscription
Information about subscribing to *The Journal of Immunology* is online at:
http://jimmunol.org/subscription

Permissions
Submit copyright permission requests at:
http://www.aai.org/About/Publications/JI/copyright.html

Email Alerts
Receive free email-alerts when new articles cite this article. Sign up at:
http://jimmunol.org/alerts

*The Journal of Immunology* is published twice each month by
The American Association of Immunologists, Inc.,
1451 Rockville Pike, Suite 650, Rockville, MD 20852
Copyright © 2010 by The American Association of
Immunologists, Inc. All rights reserved.
Print ISSN: 0022-1767 Online ISSN: 1550-6606.
BLT2 Is Upregulated in Allergen-Stimulated Mast Cells and Mediates the Synthesis of Th2 Cytokines

Kyung-Jin Cho,* Ji-Min Seo,* Min-Goo Lee,† and Jae-Hong Kim*

Mast cells are effector cells that mediate the allergic response through Ag stimulation of FcεRI. In allergic reactions, cross-linking of the surface receptors for IgE on mast cells results in the synthesis of Th2 cytokines such as IL-4 and IL-13, which are critical for the initiation and progression of the allergic response. Despite the important roles of these cytokines, the signaling mechanism by which Ag stimulation mediates the production of IL-4 and IL-13 in mast cells is not clearly understood. In the present study, we found that Ag-stimulated bone marrow-derived mast cells (BMMCs) highly upregulated the expression of BLT2, a leukotriene B4 receptor, and that blockade of BLT2 with the specific antagonist LY255283 or small interfering RNA knockdown completely abolished the production of Th2 cytokines. Furthermore, BMMCs overexpressing BLT2 showed significantly enhanced production of Th2 cytokines compared with wild-type BMMCs. Additionally, we found that the generation of Nox1-derived reactive oxygen species occurs downstream of BLT2, thus mediating the synthesis of Th2 cytokines. Taken together, our results suggest that the BLT2-Nox1-reactive oxygen species cascade is a previously unsuspected mediatory signaling mechanism to Th2 cytokine production in Ag-stimulated BMMCs, thus contributing to allergic response. The Journal of Immunology, 2010, 185: 6329–6337.

Received for publication April 15, 2010. Accepted for publication September 17, 2010.

This work was supported in part by a Korea Research Foundation grant funded by the Korean Government (Basic Research Promotion Fund; KRF-2008-313-C00603), a General Researcher Support Project grant (2010-0008295), and a Diseases Network Korea Government (Basic Research Promotion Fund; KRF-2008-313-C00603), a General Researcher Support Project grant (2010-0008295), and a Diseases Network Research Program grant (2009-0084183) from the Ministry of Education, Science and Technology, South Korea. Additionally, this work was supported by a grant from the Korea Institute of Science and Technology Institutional Research and Development Program and also by a special Korea University grant.

Address correspondence and reprint requests to Dr. Jae-Hong Kim, College of Life Sciences and Biotechnology, Korea University, College of Medicine, Seoul, Korea E-mail address: jhkim@korea.ac.kr

The online version of this article contains supplemental material.

Abbreviations used in this paper: AHR, airway hyperresponsiveness; BALF, bronchoalveolar lavage fluid; BMMC, bone marrow-derived mast cell; DCFDA, 2,7-dichloro-dihydrofluorescein diacetate; DTB4, leukotriene B4; DNP-BSA, DNP-conjugated BSA; DPI, diphenylene iodonium; FcεRI, high-affinity IgE receptor; HETE, hydroxyeicosatetraenoic acid; LTB4, leukotriene B4; NAC, N-acetylcysteine; NS, nonstimulated; RL, lung resistance; ROS, reactive oxygen species; si, small interfering; TG, transgenic; WT, wild-type.

Copyright © 2010 by The American Association of Immunologists, Inc. 0022-1767/10S16/00
together, our results suggest that the BLT2-Nox1-ROS cascade is a downstream signaling pathway mediating the synthesis of Th2 cytokines (IL-4 and IL-13) in Ag-stimulated mast cells and that targeting this pathway could be useful in the development of anti-asthma therapy.

Materials and Methods

Reagents

Mouse monoclonal anti-DNP IgE (clone SPE-7), DNPsulfated BSA (DNPS-BSA), DMSO, diphenylhexyl iodonium (DPI), and 2,7-dichlorofluorescin diacetate (DCFDA) were purchased from Sigma-Aldrich (St. Louis, MO). LTB4, 12(S)-hydroxyeicosatetraenoic acid (HETE), U75302, and LY255283 (25) were purchased from Cayman Chemical (Ann Arbor, MI). Human BLT2 (GenBank accession no. NM019839.1 under http://www.ncbi.nlm.nih.gov/UniProt/); UniProtKB/Swiss-Prot accession no. Q9NPC1 under http://www.ebi.ac.uk/interpro/) was cloned by PCR methods using the human genomic bacterial artificial chromosome library as described previously (26, 27). RPMI 1640, antibiotic, and nonessential amino acids were purchased from Invitrogen (Grand Island, NY).

BMMC culture and stimulation

The BLT2 transgenic (TG) and wild-type (WT) mice (strain FVB) used in this study have been previously described (28). Mouse BMMCs were obtained by in vitro differentiation of bone marrow cells taken from mouse femurs and cultured in RPMI 1640 supplemented with 10% FBS, 2 mM t-glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin, nonessential amino acids, 50 μM 2-ME, sodium pyruvate, and HEPES buffer containing 20 mM stem cell factor and 10 mM IL-3 (R&D Systems, Minneapolis, MN) for 4–8 wk (29). After 4 wk, 1 × 10^6 BMMCs/ml were stained with FITC-conjugated rat anti-mouse c-Kit mAb or FITC-conjugated rat IgG2a isotype control (BD Pharm Lyse; BD Biosciences, San Diego, CA) and analyzed by flow cytometry (FACSCalibur; BD Biosciences, Franklin Lakes, NJ). Purity was usually >97%. BMMCs were sensitized overnight with an optimal concentration (1 μg/ml) of monoclonal anti–DNP-specific IgE in cytokine-free medium and then serum-starved in RPMI 1640 containing 0.5% FBS for an additional 6 h before being stimulated with DNPS-BSA (100 ng/ml) for the indicated times.

Flow cytometric analysis of BLT2 expression

To analyze the level of BLT2 expression, cells were fixed with 3% paraformaldehyde and permeabilized with 0.1% Triton X-100 in PBS. After being blocked with 2% BSA for 30 min, cells were incubated with the primary Ab (rabbit polyclonal anti-BLT2; Cayman Chemical) (30–32). Cells were then washed three times with PBS and incubated with FITC-conjugated anti-rabbit IgG (Invitrogen, Carlsbad, CA). Cells (10,000/sample) were then analyzed with a flow cytometer (FACSCalibur; BD Biosciences) using CellQuest software, as described previously (32). Data are expressed as the mean fluorescence intensity.

Semiquantitative RT-PCR for BLT1, BLT2, Nox1, IL-4, and IL-13

Total cellular RNA was extracted using easy-BLUE (Intron, Sungnam, Korea), after which 2 μg of the extracted RNA was reverse-transcribed using Molerance murine leukemia virus reverse transcriptase (Invitrogen) and amplified for BLT1, BLT2, Nox1, IL-4, IL-13, and GAPDH using an RT-PCR PreMix kit (Intron). For semiquantitative analysis of transcripts, we first determined the optimal PCR conditions for linear amplification of GAPDH. The primers used were 5′-AATGCCAGCAGATGGAGT-3′ (forward) and 5′-GATGAGAAGCAAAGGAATGA-3′ (reverse) for Nox1; 5′-CGTATGAGCTGATGTTGTC-3′ (forward) and 5′-GATGAGACCACTTTGTTTTGC-3′ (reverse) for IL-4; and 5′-ATCTACAAGGACCAGGATGTTG-3′ (forward) and 5′-GATGAGACCACTTTGTTTTGC-3′ (reverse) for IL-13. The primers for BLT1 and BLT2 have been previously described (24). The specificity of all the primers was confirmed by sequencing the PCR products.

Real-time PCR

For the real-time PCR reactions, a LightCycler 480 SYBR Green I Master (Roche Diagnostics, Mannheim, Germany) was used according to the manufacturer’s instructions.

Measurement of cytokines

The sensitized BMMCs were stimulated with DNPS-BSA (100 ng/ml) for 24 h, after which the conditioned media were collected and immediately frozen. The collected media were then lyophilized, and the levels of IL-4 and IL-13 were quantified using an ELISA kit (BD Biosciences) according to the manufacturer’s instructions.

RNA interference for BLT2 and Nox1

To knock down BLT2 or Nox1, BMMCs were transfected with BLT2 siRNA (Bioneer, Daejeon, Korea) or Nox1 siRNA (Invitrogen) using the MP-100 MicroPorator (Digital Bio, Seoul, Korea) according to the manufacturers’ instructions. Briefly, 1 × 10^6 cells in 100 μl of resuspension buffer (Digital Bio) containing scrambled siRNA, BLT2 siRNA, or Nox1 siRNA (final 50 nM) were electroporated using one pulse of 1400 V for 30 ms. Cells were cultured in complete medium without antibiotics for 48 h, and the mRNA level of BLT2 or Nox1 was then analyzed by RT-PCR to evaluate the level of interference.

BLT2-overexpressing BMMCs

To prepare BLT2-overexpressing cells, BMMCs (1 × 10^6 cells) were transiently transfected with pcdNA3.1-BLT2 (27) or pcdNA3.1 using the MP-100 MicroPorator according to the manufacturer’s instructions. Briefly, 1 × 10^6 cells in 100 μl resuspension buffer containing 2 μg pcdNA3.1-BLT2 or pcdNA3.1 were electroporated using one pulse of 1400 V for 30 ms.

Measurement of ROS

Intracellular ROS levels were determined by measuring DCF fluorescence with a flow cytometer (FACSCalibur) as previously described (33). Briefly, BMMCs were incubated for 20 min with the ROS-sensitive fluorophore DCFDA (10 μM), washed with PBS, and immediately analyzed.

Sensitization and challenge of mice

Female BALB/c mice (7 wk old; 18–20 g) were obtained from Orient Bio (Seoungnam, Korea). BALB/c mice were sensitized on day 1 by i.p. injection of 20 μg OVA emulsified in 2.5 mg of alum (Pierce, Rockford, IL), followed by an identical booster injection administered on day 14. On days 21, 22, and 23 after initial sensitization, the mice were challenged for 30 min with an aerosol of 1% OVA using an ultrasonic nebulizer. LY255283 (5 mg/kg; Cayman Chemical) or vehicle control (DMSO) was administered i.v. 1 h before challenge with 1% OVA. Mice were killed on day 25 to assess asthmatic phenotypes. All experimental animals used in this study were treated according to guidelines approved by the Institutional Animal Care and Use Committee of Korea University.

Determination of AHR in response to methacholine

Airway function was assessed by measuring changes in lung resistance (R L) and dynamic compliance in response to increasing doses (from 5 to 40 mg/ml) of inhaled methacholine aerosol. AHR was measured in unrestrained, conscious mice at 24 h after the final OVA challenge using a whole-body plethysmograph, as previously described (34). The mice were tracheostomized under anesthesia and connected to a computer-controlled small-animal ventilator (flexiVent; Scireq, Montreal, Quebec, Canada).

Data analysis and statistics

Most of the data were assessed by the Student t test and expressed as mean ± SD. One-way ANOVA was used for comparison of multiple groups. In all cases the experiments were repeated three times with similar results and representative data are shown. The p values <0.05 were considered to indicate statistical significance.

Results

Ag stimulation induces Th2 cytokine production via BLT2 upregulation in BMMCs

To determine whether BLT2 is associated with the Ag-stimulated signaling that regulates Th2 cytokine synthesis in mast cells, we first measured the expression level of BLT2 in BMMCs using FACS analysis with BLT2-specific Ab. As shown in Fig. 1A, non-stimulated (NS) cells showed a rightward-shifted peak relative to cells stained with the isotype control (IgG), indicating that BLT2 is expressed in these cells. Ag stimulation of BMMCs with DNP-
BSA shifted the FACS curve to the right compared with nonstimulated cells, suggesting that Ag stimulation induces upregulation of BLT2 expression. Additionally, BLT2 transcript levels were analyzed by semiquantitative RT-PCR. The PCR analysis clearly demonstrated that the level of BLT2 transcripts in BMMCs was significantly upregulated by Ag treatment, with a maximal effect after 20–40 min of Ag treatment (Fig. 1B).

Mast cells are known to produce Th2 cytokines in response to Ag stimulation (35, 36). Consistent with these reports, we observed that the levels of IL-4 and IL-13 transcripts in BMMCs, as detected by semiquantitative RT-PCR (Fig. 1B) and real-time PCR analysis (Fig. 1C), are markedly elevated following Ag stimulation. We also measured the levels of IL-4 and IL-13 protein by ELISA. The synthesis of these Th2 cytokines was significantly elevated in a time-dependent manner following Ag stimulation of BMMCs (Fig. 1D).

To test whether BLT2 plays any role in Ag stimulation-induced Th2 cytokine synthesis, we analyzed the effect of BLT2 blockade on Th2 cytokine levels using a BLT2-specific antagonist, LY255283 (24), and siRNA BLT2 knockdown. Treatment of BMMCs with LY255283 resulted in a dramatic attenuation of Ag-induced upregulation of Th2 cytokine transcripts (Fig. 2A, B). Similarly, knockdown of BLT2 using siRNA markedly reduced the Ag-stimulated induction of IL-4 and IL-13 at both the transcript and the protein level (Fig. 2C, 2E, 2F). Under these experimental conditions, the knockdown effect of BLT2 siRNA was clearly observed at the

FIGURE 1. Ag-induced Th2 cytokine synthesis in BMMCs is dependent on BLT2. A, BMMCs were stimulated with DNP-BSA (100 ng/ml) for 12 h and incubated with FITC-conjugated anti-BLT2 or an isotype control Ab (IgG). BLT2 expression was evaluated by flow cytometry. The results shown are representative of three independent experiments with similar results. B and C, BMMCs were activated with 100 ng/ml DNP-BSA for the indicated times, and the levels of BLT2, IL-4, and IL-13 were assessed by semiquantitative RT-PCR or real-time PCR. Data are means ± SD of three independent experiments. *p < 0.05 versus no treatment. D, BMMCs were incubated with 100 ng/ml DNP-BSA for the indicated times and the secretion of IL-4 or IL-13 was determined using a specific ELISA assay. Data are means ± SD of three independent experiments. *p < 0.05 versus no treatment. NS, nonstimulated.

FIGURE 2. BLT2 inhibition attenuates Ag-induced Th2 cytokine synthesis in BMMCs. A and B, BMMCs were pretreated for 30 min with LY255283 (10 μM) or DMSO and then activated with DNP-BSA (100 ng/ml) for 1 h. Thereafter, total cellular RNA was isolated and examined with semiquantitative RT-PCR or real-time PCR. Data are means ± SD of three independent experiments. *p < 0.05; **p < 0.01 versus no treatment. C, BMMCs were transfected with Scr siRNA or BLT2 siRNA (50 nM). After 24 h, cells were stimulated with DNP-BSA (100 ng/ml) for 1 h; total cellular RNA was then isolated, and the transcript levels of BLT2, IL-4, and IL-13 were assessed by semiquantitative RT-PCR. The results shown are representative of three independent experiments with similar results. D, BMMCs were transfected with Scr siRNA or BLT2 siRNA (50 nM). After 24 h, cells were stimulated with DNP-BSA (100 ng/ml) for 12 h and incubated with FITC-conjugated anti-BLT2 or isotype control Ab (IgG). E and F, BMMCs were transfected with Scr siRNA or BLT2 siRNA (50 nM) for 24 h and then activated with DNP-BSA (100 ng/ml) for 24 h. The levels of IL-4 and IL-13 were determined using a specific ELISA assay. Data are means ± SD of three independent experiments. *p < 0.05 versus DNP-BSA–induced cytokine synthesis in Scr siRNA-transfected cells.
protein expression level (~50% decrease in BLT2 protein) based on FACS analysis (Fig. 2D). This pattern is similar to that observed at the transcript level, as shown in Fig. 2C. Taken together, these results suggest that BLT2 is necessary for Ag-induced Th2 cytokine synthesis in BMMCs.

**BLT2 overexpression is sufficient to induce the production of Th2 cytokines in BMMCs**

To further examine whether BLT2 is involved in the synthesis of IL-4 and IL-13 in Ag-stimulated mast cells, we prepared BMMCs that overexpress BLT2 by transiently transfecting the cells with a BLT2 expression plasmid (27). As shown in Fig. 3A, BLT2 expression alone resulted in a modest increase in the levels of transcripts for IL-4 and IL-13 cytokines. The addition of BLT2 ligands [LTB4 and 12(S)-HETE] further enhanced the levels of IL-4 and IL-13 transcripts in BLT2-overexpressing BMMCs compared with cells transfected with a control vector (Fig. 3A). Similarly, the protein levels of IL-4 and IL-13 were also modestly increased by BLT2 overexpression alone; the addition of BLT2 ligands further enhanced cytokine synthesis (Fig. 3B, 3C). In contrast to BLT2, BLT1 overexpression had no significant effect on cytokine production in BMMCs (data not shown).

To further examine the role of BLT2 in Th2 cytokine synthesis, we compared BMMCs from WT and BLT2 TG mice (28). We isolated BMMCs from WT and BLT2 TG mice and analyzed the levels of these cytokines using real-time PCR and ELISA. Our results clearly show that the levels of IL-4 and IL-13 are significantly enhanced in BMMCs derived from BLT2 TG mice compared with cells derived from WT animals (Fig. 4A–C). The addition of BLT2 ligands [LTB4 or 12(S)-HETE] further enhanced the production of IL-4 and IL-13 in BLT2 TG BMMCs. Furthermore, BLT2 knockdown with siRNA dramatically attenuated LTB4- and 12(S)-HETE–induced Th2 cytokine synthesis in TG BMMCs at both the transcript and the protein levels (Fig. 4D–F).

**BLT2 regulates Ag-stimulated cytokine production via a Nox1-ROS–dependent pathway**

A number of previous reports have shown that Ag-stimulated mast cells exhibit elevated ROS generation and that FcεRI-dependent ROS generation is diminished by treatment with DPI, an inhibitor of flavoenzymes, including NADPH oxidase (7–9, 37). Consistent with these reports, we found that ROS levels in BMMCs are indeed elevated following Ag stimulation (Supplemental Fig. 1A) and that pretreatment with DPI or NAC, a free radical scavenger, significantly attenuated intracellular ROS production induced by Ag stimulation in BMMCs (Supplemental Fig. 1A). These results suggest a possible role for NADPH oxidases (Nox family) in Ag-stimulated ROS generation in mast cells. To test whether ROS play any role in Ag-stimulated Th2 cytokine synthesis in mast cells, BMMCs were pretreated with DPI or NAC; cells were then stimulated with Ag and the levels of Th2 cytokines were measured using quantitative RT-PCR or real-time PCR. Our results clearly demonstrate that DPI and NAC significantly inhibit Ag stimulation-induced IL-4 and IL-13 upregulation (Supplemental Fig. 1B, 1C), suggesting that ROS play a role in the FcεRI signaling pathway for IL-4 and IL-13 in BMMCs.

We recently reported that Nox-derived ROS generation lies downstream of BLT2 (18, 32, 38). Based on this, we hypothesized that one potential mechanism of ROS generation could be through a BLT2-Nox–linked cascade in Ag-stimulated mast cells. In the present study, we tested this hypothesis and found that Ag-induced ROS generation is dramatically inhibited by BLT2 siRNA (Fig. 5A). Additionally, we found that Nox1 transcript levels are highly upregulated following Ag stimulation in BMMCs and that this Ag-induced Nox1 upregulation is significantly suppressed by BLT2 siRNA (Fig. 5B), suggesting that the elevation of Nox1-ROS levels occurs through a BLT2-dependent pathway in BMMCs. To further analyze the role of Nox1 in Ag-induced ROS generation, we transiently transfected BMMCs with Nox1 siRNA and analyzed changes in ROS levels in response to Ag stimulation. When Nox1 was knocked down by siRNA, Ag-induced Nox1 upregulation and subsequent ROS generation was significantly reduced (Fig. 5C, 5D). Importantly, the Ag-induced upregulation of Th2 cytokine transcripts was also evidently attenuated by siRNA knockdown of Nox1 (Fig. 5D). Similarly, the protein levels of Th2 cytokines, as analyzed by ELISA, were also markedly diminished by siNox1 (Fig. 5E, 5F), indicating that Nox1-derived ROS generation acts as a downstream component in the BLT2 pathway leading to IL-4 and IL-13 synthesis in Ag-stimulated mast cells.

The proposed action of this Nox1-derived ROS generation downstream of BLT2 was further analyzed by overexpressing BLT2 in BMMCs. To accomplish this, we transiently transfected cells with a BLT2 expression plasmid and then measured the levels of ROS generation and Nox1 transcripts. Simply by overexpressing BLT2, we could observe modestly increased levels of ROS generation and Nox1 transcripts; the addition of BLT2 ligands [300 nM LTB4 and 12(S)-HETE] further enhanced these effects (Fig. 6). Similar results were obtained in BMMCs derived from BLT2 TG mice; in these cells, the addition of BLT2 ligands resulted in further en-
hancement of the levels of ROS generation and Nox1 transcripts (Fig. 7A, 7B). However, transfection with BLT2 siRNA apparently abolished these effects (Fig. 7A, 7B). Additionally, knockdown of Nox1 by siNox1 in these cells significantly attenuated the BLT2 ligand-induced upregulation of both IL-4 and IL-13 transcript (Fig. 7C) and protein (Fig. 7D, 7E) levels. Taken together, these

FIGURE 5. Ag-induced ROS generation and Th2 cytokine synthesis in BMMCs occurs through a BLT2-Nox1 cascade. A and B, BMMCs were transfected with Scr siRNA or BLT2 siRNA (50 nM); after 24 h, they were stimulated with DNP-BSA (100 ng/ml) for 1 h. A, DCFDA (10 μM) was added for 20 min before ROS measurement. Intracellular ROS were measured by FACS analysis of DCF fluorescence. **p < 0.01 versus DNP-BSA–induced DCF fluorescence in Scr siRNA-transfected cells. B, Total cellular RNA was isolated and the levels of BLT2 and Nox1 transcripts were assessed by semiquantitative RT-PCR. The results shown are representative of three independent experiments with similar results. C and D, BMMCs were transfected with Scr siRNA or Nox1 siRNA (50 nM); after 24 h, they were stimulated with DNP-BSA (100 ng/ml) for 1 h. C, DCFDA (10 μM) was added for 20 min before ROS measurement. Intracellular ROS were measured by FACS analysis of DCF fluorescence. **p < 0.01 versus DNP-BSA–induced DCF fluorescence in Scr siRNA-transfected cells. D, Semiquantitative RT-PCR was performed to detect the transcript levels of Nox1, IL-4, and IL-13. E and F, BMMCs were transfected with Scr siRNA or Nox1 siRNA (50 nM) for 24 h; the cells were then activated with DNP-BSA (100 ng/ml) for 24 h. The levels of IL-4 and IL-13 were determined using a specific ELISA assay. Data are means ± SD of three independent experiments (**p < 0.01).
data further support the idea that Nox1-derived ROS generation lies downstream of BLT2 and thus mediates the synthesis of Th2 cytokines in mast cells.

**BLT2 blockade suppresses the synthesis of Th2 cytokines in mice with OVA-induced asthma**

Recently, we reported that BLT2 plays a pivotal mediatory role in the pathogenesis of asthma (24). To determine whether BLT2 plays a role in Th2 cytokine production in vivo, we tested the OVA-induced asthma mouse model. We measured the levels of cytokines in the lung tissue and bronchoalveolar lavage fluid (BALF) of mice with OVA-induced asthma to assess the effect of BLT2 inhibition on the levels of Th2 cytokines associated with asthmatic responses. In lungs from mice with OVA-induced asthma, IL-4 and IL-13 levels were significantly higher in the lung tissue of BLT2 TG mice compared with those of normal control mice, and these levels were further enhanced by OVA challenge (Fig. 8D, 8E). Interestingly, we found that BLT2 TG mice showed a markedly increased RLR with increasing doses of methacholine (5–40 mg/ml) (Fig. 8F). This RLR value is comparable to that observed in OVA-challenged asthma mice that received 40 mg/ml methacholine (Fig. 8F), suggesting that the elevated levels of IL-4 and IL-13 in BLT2 TG mice may contribute to the enhanced AHR.

**Discussion**

In the present study, we found that Ag-stimulated synthesis of IL-4 and IL-13 in BMMCs occurs through a BLT2-dependent pathway. Additionally, our results demonstrate that Nox1-derived ROS generation lies downstream of BLT2 in mediating FcεRI signaling that affects Th2 cytokine synthesis in Ag-stimulated mast cells. The induced BLT2 expression and subsequent ROS generation via Nox1 upregulation are suggested to be critical for the synthesis of Th2 cytokines in Ag-stimulated mast cells, mediating the early asthmatic/allergic response. The role of BLT2 in the synthesis of Th2 cytokines was verified in BLT2 TG mice.

Mast cells play a central role in the production of Th2 cytokines following Ag-stimulated FcεRI aggregation during the early allergic response (2). When allergic individuals are exposed to allergens, cross-linking of IgE on the surface of mast cells leads to the release of mediators, including Th2 cytokines, which cause early allergic responses (2, 39–41). Mast cell-derived factors play a critical role in sustaining the inflammatory response and in the recruitment of other immune cells, such as T cells, neutrophils, and macrophages, to inflammatory sites. The recruited T cells are also found in high numbers at sites of allergic inflammation, including the lungs of asthmatic patients, and are known as another source of Th2 cytokines, including IL-4, IL-5, and IL-13 (42, 43). IL-4 and IL-13 are key cytokines in the pathogenesis of asthma (3–5, 42, 43). Expression of IL-4 in the lungs of IL-4 TG mice elicits an inflammatory response characterized by epithelial cell hypertrophy, accumulation of macrophages, lymphocytes, eosinophils, and neutrophils, and an AHR response to inhaled methacholine (3, 42). Similarly, chronic pulmonary overexpression of IL-13 in mouse lungs results in a complex phenotype characterized by an eosinophil inflammatory response, goblet cell hyperplasia, and subepithelial fibrosis (4, 43). IL-13 also acts directly on bronchial tissues to promote mucus production and AHR (4, 43). Additionally, elevated IL-13 levels have been detected in the airways and sputum of patients with asthma (43).

Recent studies have demonstrated that stimulation of mast cells through FcεRI induces the production of intracellular ROS, which act as second messengers in a signal transduction pathway leading to degranulation and cytokine synthesis (7–9, 37, 44, 45). We also previously reported that the BLT2 cascade plays a mediatory role in the generation of ROS (18, 32, 48). Additionally, previous studies have reported that BLT2 is expressed in human and murine mast cells (23). Based on this evidence, we hypothesized that one potential mechanism by which Ag-FcεRI stimulation mediates IL-4 and IL-13 synthesis in BMMCs could be through a BLT2-dependent pathway. In the present study, we showed that ROS generation in BMMCs is increased by the addition of Ag and that this enhanced ROS production is dramatically inhibited by treatment of BMMCs with BLT2 siRNA. To examine whether Nox mediates ROS generation, we analyzed the mRNA levels of Nox family members in mouse BMMCs. Incubation with Ag induced the upregulation of Nox1 transcripts but had no effect on Nox2 or Nox4 transcript levels (data not shown), and transfection with siNox1 markedly reduced Ag-mediated ROS generation and Th2 cytokine production in BMMCs (Fig. 5C–F). These data suggest that Nox1 acts downstream of ROS generation in Ag-stimulated mast cells, thus mediating the synthesis of Th2 cytokines. Consistent with our observation, DPI-sensitive flavoenzymes such as...
Nox were previously suggested to be involved in Ag-mediated ROS production in mast cells (44, 45). We found that transient transfection with a BLT2 expression plasmid alone caused a modest increase in Nox1 transcript levels, ROS generation, and Th2 cytokine synthesis and that the addition of BLT2 ligands further increased these effects (Figs. 6, 7). Finally, in BMMCs from BLT2 TG mice, the levels of Nox1 transcripts, ROS generation, and IL-4/IL-13 synthesis were modestly enhanced compared with WT BMMCs (data not shown; Fig. 4A–C). The addition of BLT2 ligands further enhanced these effects, which were completely increased these effects (Figs. 6, 7). Finally, in BMMCs from BLT2 TG mice, the levels of Nox1 transcripts, ROS generation, and IL-4/IL-13 synthesis were modestly enhanced compared with WT BMMCs (data not shown; Fig. 4A–C). The addition of BLT2 ligands further enhanced these effects, which were completely increased these effects (Figs. 6, 7). Finally, in BMMCs from BLT2 TG mice, the levels of Nox1 transcripts, ROS generation, and IL-4/IL-13 synthesis were modestly enhanced compared with WT BMMCs (data not shown; Fig. 4A–C). The addition of BLT2 ligands further enhanced these effects, which were completely increased these effects (Figs. 6, 7). Finally, in BMMCs from BLT2 TG mice, the levels of Nox1 transcripts, ROS generation, and IL-4/IL-13 synthesis were modestly enhanced compared with WT BMMCs (data not shown; Fig. 4A–C). The addition of BLT2 ligands further enhanced these effects, which were completely increased these effects (Figs. 6, 7). Finally, in BMMCs from BLT2 TG mice, the levels of Nox1 transcripts, ROS generation, and IL-4/IL-13 synthesis were modestly enhanced compared with WT BMMCs (data not shown; Fig. 4A–C). The addition of BLT2 ligands further enhanced these effects, which were completely increased these effects (Figs. 6, 7). Finally, in BMMCs from BLT2 TG mice, the levels of Nox1 transcripts, ROS generation, and IL-4/IL-13 synthesis were modestly enhanced compared with WT BMMCs (data not shown; Fig. 4A–C). The addition of BLT2 ligands further enhanced these effects, which were completely increased these effects (Figs. 6, 7). Finally, in BMMCs from BLT2 TG mice, the levels of Nox1 transcripts, ROS generation, and IL-4/IL-13 synthesis were modestly enhanced compared with WT BMMCs (data not shown; Fig. 4A–C). The addition of BLT2 ligands further enhanced these effects, which were completely increased these effects (Figs. 6, 7). Finally, in BMMCs from BLT2 TG mice, the levels of Nox1 transcripts, ROS generation, and IL-4/IL-13 synthesis were modestly enhanced compared with WT BMMCs (data not shown; Fig. 4A–C). The addition of BLT2 ligands further enhanced these effects, which were completely increased these effects (Figs. 6, 7). Finally, in BMMCs from BLT2 TG mice, the levels of Nox1 transcripts, ROS generation, and IL-4/IL-13 synthesis were modestly enhanced compared with WT BMMCs (data not shown; Fig. 4A–C). The addition of BLT2 ligands further enhanced these effects, which were completely increased these effects (Figs. 6, 7). Finally, in BMMCs from BLT2 TG mice, the levels of Nox1 transcripts, ROS generation, and IL-4/IL-13 synthesis were modestly enhanced compared with WT BMMCs (data not shown; Fig. 4A–C). The addition of BLT2 ligands further enhanced these effects, which were completely increased these effects (Figs. 6, 7). Finally, in BMMCs from BLT2 TG mice, the levels of Nox1 transcripts, ROS generation, and IL-4/IL-13 synthesis were modestly enhanced compared with WT BMMCs (data not shown; Fig. 4A–C). The addition of BLT2 ligands further enhanced these effects, which were completely increased these effects (Figs. 6, 7). Finally, in BMMCs from BLT2 TG mice, the levels of Nox1 transcripts, ROS generation, and IL-4/IL-13 synthesis were modestly enhanced compared with WT BMMCs (data not shown; Fig. 4A–C). The addition of BLT2 ligands further enhanced these effects, which were completely increased these effects (Figs. 6, 7). Finally, in BMMCs from BLT2 TG mice, the levels of Nox1 transcripts, ROS generation, and IL-4/IL-13 synthesis were modestly enhanced compared with WT BMMCs (data not shown; Fig. 4A–C). The addition of BLT2 ligands further enhanced these effects, which were completely increased these effects (Figs. 6, 7). Finally, in BMMCs from BLT2 TG mice, the levels of Nox1 transcripts, ROS generation, and IL-4/IL-13 synthesis were modestly enhanced compared with WT BMMCs (data not shown; Fig. 4A–C). The addition of BLT2 ligands further enhanced these effects, which were completely increased these effects (Figs. 6, 7). Finally, in BMMCs from BLT2 TG mice, the levels of Nox1 transcripts, ROS generation, and IL-4/IL-13 synthesis were modestly enhanced compared with WT BMMCs (data not shown; Fig. 4A–C). The addition of BLT2 ligands further enhanced these effects, which were completely increased these effects (Figs. 6, 7). Finally, in BMMCs from BLT2 TG mice, the levels of Nox1 transcripts, ROS generation, and IL-4/IL-13 synthesis were modestly enhanced compared with WT BMMCs (data not shown; Fig. 4A–C). The addition of BLT2 ligands further enhanced these effects, which were completely increased these effects (Figs. 6, 7). Finally, in BMMCs from BLT2 TG mice, the levels of Nox1 transcripts, ROS generation, and IL-4/IL-13 synthesis were modestly enhanced compared with WT BMMCs (data not shown; Fig. 4A–C). The addition of BLT2 ligands further enhanced these effects, which were completely
abandoned by siRNA knockdown of Nox1 (Fig. 7). Taken together, these results suggest that Nox1 upregulation and subsequent ROS generation lie downstream of BLT2 and that this BLT2-Nox1-ROS cascade is responsible for increased Th2 cytokine synthesis in Ag-stimulated mast cells.

Our observation that the ROS levels in the BALF of BLT2 TG mice are significantly increased compared with those of normal mice (data not shown) supports the idea that ROS generation lies downstream of BLT2. The presence of enhanced basal levels of IL4 and IL-13 in the lung tissue of BLT2 TG mice is likely to be responsible for the enhanced AHR, as assessed by the Rq (Fig. 8F) that occurs in these animals when they are given increasing doses of methacholine. However, the details of the mechanism by which enhanced Rq occurs in BLT2 TG mice that do not undergo OVA challenge remain to be determined. Further studies are necessary to understand the detailed underlying mechanisms by which mast cells contribute to the synthesis of IL-4 and IL-13 in BLT2 TG mice (Fig. 8D, 8E) and/or to what extent the BLT2 upregulated mast cells contribute to the elevated levels of IL-4 and IL-13 in our murine model of allergic asthma (Fig. 8A–C).

To our knowledge, this is the first report that defines the role of BLT2 in ROS generation and Th2 cytokine synthesis in Ag-stimulated mast cells. We suggest that BLT2 upregulation in mast cells following Ag stimulation is critical for ROS generation and subsequent Th2 cytokine synthesis and that these processes are essential for initiating and sustaining the allergic response in the airway. A better understanding of the BLT2-linked pathway in mast cells and the possible role of BLT2-mediated allergic signaling in other cell types will help us to clarify their roles in the pathogenesis of Ag-induced allergic reactions. Furthermore, our finding that a BLT2-Nox1-ROS cascade is involved in Ag-stimulated Th2 cytokine synthesis in mast cells could serve as the basis for the development of new treatments for allergic disease.

Disclosures
The authors have no financial conflicts of interest.

References


